Lenalidomide (LENA) Hybrid Gold Complex Nanoparticles: Synthesis, Physicochemical Evaluation, and Perspectives in Nanomedicine.

Celia Arib, Jolanda Spadavecchia

RetractedOpen access · goldAbstract readRetracted Publication

In one paragraph

Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

0.3field-weighted citation impact, top 51% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

Lenalidomide promotes melarsoprol-activated cGAS-STING-mediated immunotherapy for hepatocellular carcinomaFundamental research · 2025
Article
Targeted Drug Delivery for Chronic Lymphocytic Leukemia.Pharmaceutical research · 2022
Review
Effect on Human Vascular Endothelial Cells of Au Nanoparticles Synthesized fromACS omega · 2021
Article

4 · The record

Corrections and comments

Retraction · 2025-06-25Duplication of Data · Duplication of/in Image · Error in Methods · Investigation by Company/Institution · · see also: https://pubpeer.com/publications/0F0834D983EB389EA7656670E83747; See also: https://mis.cnrs.fr/wp-content/uploads/2025/05/Recommandations.pdf
Retracted
Retraction of "Lenalidomide (LENA) Hybrid Gold Complex Nanoparticles: Synthesis, Physicochemical Evaluation, and Perspectives in Nanomedicine".2025

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Celia AribCNRS, UMR 7244, NBD-CSPBAT, Laboratory of Chemistry, Structures and Properties of Biomaterials and Therapeutic Agents University Paris 13, Sorbonne Paris Nord, 93000 Bobigny, France.

Jolanda SpadavecchiaCNRS, UMR 7244, NBD-CSPBAT, Laboratory of Chemistry, Structures and Properties of Biomaterials and Therapeutic Agents University Paris 13, Sorbonne Paris Nord, 93000 Bobigny, France.

Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper proposes a fast methodology to synthesize hybrid lenalidomide gold nanoparticles. Gold (HAuCl

Identifiers

PMID33195898

DOI10.1021/acsomega.0c02644

PMCPMC7658941

OpenAlexW3096945455

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.